TopicalDosed ingredientTherapeutic flag Cosmetic cross-reference

Avobenzone

CAS 70356-09-1

Avobenzone (CAS 70356-09-1) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 95 adverse event associations.

SOURCE NLM DailyMed
Label records
8
SOURCE EMBL-EBI ChEMBL
Bioactivity
4
SOURCE DrugCentral
Adverse signals
95
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Avobenzone
CAS Number
70356-09-1
UNII
G63QQF2NOX
InChIKey
XNEFYCZVKIDDMS-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1200522
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredientnatural producttherapeutic flagtopical
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1200522 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE NLM DailyMed 8 label rows

Drug Label Active Ingredients

Active ingredient and active moiety rows from source drug product labels.

ProductIngredient Active MoietyEffective
Neutrogena Ultra Sheer Dry Touch Sunscreen Broad Spectrum SPF 70 AVOBENZONE
G63QQF2NOX
 AVOBENZONE 20260505
SPF 50 Dry Tropix with fragrance AVOBENZONE
G63QQF2NOX
 AVOBENZONE 20260505
SURFACE SUN SPF 50 DRY TOUCH Fragrance Free AVOBENZONE
G63QQF2NOX
 AVOBENZONE 20260505
SURFACE SUN SPF 50 DRY TOUCH Fragrance Free AVOBENZONE
G63QQF2NOX
 AVOBENZONE 20260505
SURFACE SUN SPF30 DRY TOUCH Fragrance Free AVOBENZONE
G63QQF2NOX
 AVOBENZONE 20260505
THANKYOU FARMER Sun Project Moisture Sun AVOBENZONE
G63QQF2NOX
 AVOBENZONE 20260505
THANKYOU FARMER Sun Project Soothing Sun AVOBENZONE
G63QQF2NOX
 AVOBENZONE 20260505
No 7 Prime Forever SPF 50 Primer AVOBENZONE
G63QQF2NOX
 AVOBENZONE 20260430
SOURCE EMBL-EBI ChEMBL 4 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 26740.246875 nM 31 -
- IC50 19976.309999999998 nM 1 -
- AC50 3162.3 nM 1 -
Tyrosinase
Enzyme
 INHIBITOR - - Homo sapiens
SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Macular degeneration 264 795.966 10025409
Therapy interrupted 140 279.084 10066377
Chronic sinusitis 94 240.591 10009137
Paraesthesia oral 98 217.677 10057372
Procedural pain 98 208.379 10064882
Therapy cessation 100 161.781 10065154
Death 382 150.299 10011906
Vaginal flatulence 39 124.567 10064227
Body tinea 33 116.471 10005913
Female genital tract fistula 42 105.197 10061149
Radiculopathy 44 94.727 10037779
Proctitis 40 94.418 10036774
Infection susceptibility increased 33 92.198 10021866
Inhibitory drug interaction 33 89.68 10068071
Vaginal discharge 39 87.758 10046901
Removal of foreign body 15 85.827 10062102
Surgery 68 83.076 10042609
Therapeutic product effect incomplete 127 82.873 10082200
Cardiac arrest 125 78.823 10007515
Dyspepsia 104 73.331 10013946
Anal inflammation 21 69.737 10050247
Glucose tolerance impaired 34 69.505 10018429
Poor quality sleep 47 64.87 10062519
Methaemoglobinaemia 28 64.109 10027496
Foetal death 35 63.124 10055690
Drug ineffective 463 62.705 10013709
SARS-CoV-2 test negative 18 58.756 10084273
Local anaesthetic systemic toxicity 17 56.927 10082534
Impaired quality of life 37 55.612 10076936
Hospitalisation 92 55.229 10054112
Bone density decreased 34 51.749 10049470
Purpura 36 49.913 10037549
Colitis ulcerative 48 49.201 10009900
Product packaging confusion 15 46.794 10074776
Appendicolith 24 44.537 10074458
Oral candidiasis 41 44.459 10030963
Impaired work ability 35 43.839 10052302
Hyperlipidaemia 39 42.085 10062060
Tracheal deviation 9 42.003 10044287
Frequent bowel movements 40 40.76 10017367
Foreign body 17 40.522 10070245
Pyrexia 254 40.486 10037660
Ventricular fibrillation 39 40.452 10047290
Anaphylactic shock 41 39.954 10002199
Skin disorder 43 39.719 10040831
Constipation 142 38.232 10010774
Proctalgia 24 36.924 10036772
Phrenic nerve paralysis 9 36.042 10064964
Accident 23 36.026 10000369
Oral herpes 36 35.98 10067152

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 3 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
AVOBENZONE 45045 SU MTHSPL
Avobenzone 45045 SU MTHSPL
avobenzone 45045 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Avobenzone used for in pharmaceutical contexts?

Avobenzone (CAS 70356-09-1) appears in DailyMed active-ingredient label rows, including Neutrogena Ultra Sheer Dry Touch Sunscreen Broad Spectrum SPF 70, SPF 50 Dry Tropix with fragrance, SURFACE SUN SPF 50 DRY TOUCH Fragrance Free.

What are the known adverse events for Avobenzone?

Avobenzone has 95 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Macular degeneration, Therapy interrupted, Chronic sinusitis, Paraesthesia oral, Procedural pain. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Avobenzone also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Avobenzone with EU status "permitted".

What clinical phase is Avobenzone in?

Avobenzone is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Avobenzone?

Avobenzone has 4 bioactivity rows in this page query. Rendered target entries include Tyrosinase.